| Date | Time | Source | Headline | Symbol | Company |
| 06/03/2024 | 8:30AM | GlobeNewswire Inc. | FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device | NASDAQ:NXLIW | Nexalin Technologies Inc |
| 05/23/2024 | 5:17PM | Edgar (US Regulatory) | Form S-1 - General form for registration of securities under the Securities Act of 1933 | NASDAQ:NXLIW | Nexalin Technologies Inc |
| 05/22/2024 | 8:30AM | GlobeNewswire Inc. | Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts | NASDAQ:NXLIW | Nexalin Technologies Inc |
| 05/21/2024 | 4:39PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:NXLIW | Nexalin Technologies Inc |
| 05/14/2024 | 4:54PM | Edgar (US Regulatory) | Form RW - Registration Withdrawal Request | NASDAQ:NXLIW | Nexalin Technologies Inc |
| 05/10/2024 | 2:50PM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:NXLIW | Nexalin Technologies Inc |
| 05/09/2024 | 8:30AM | GlobeNewswire Inc. | Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23 | NASDAQ:NXLIW | Nexalin Technologies Inc |
| 04/25/2024 | 10:44AM | GlobeNewswire Inc. | Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements | NASDAQ:NXLIW | Nexalin Technologies Inc |
| 04/09/2024 | 8:30AM | GlobeNewswire Inc. | Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing | NASDAQ:NXLIW | Nexalin Technologies Inc |
| 04/04/2024 | 1:00PM | GlobeNewswire Inc. | Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device | NASDAQ:NXLIW | Nexalin Technologies Inc |
| 04/02/2024 | 8:30AM | GlobeNewswire Inc. | Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board | NASDAQ:NXLIW | Nexalin Technologies Inc |
| 03/28/2024 | 8:30AM | GlobeNewswire Inc. | Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego | NASDAQ:NXLIW | Nexalin Technologies Inc |
| 03/14/2024 | 8:30AM | GlobeNewswire Inc. | Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology | NASDAQ:NXLIW | Nexalin Technologies Inc |
| 03/13/2024 | 8:30AM | GlobeNewswire Inc. | Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment” | NASDAQ:NXLIW | Nexalin Technologies Inc |
| 02/08/2024 | 8:30AM | GlobeNewswire Inc. | Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device | NASDAQ:NXLIW | Nexalin Technologies Inc |
| 01/23/2024 | 8:30AM | GlobeNewswire Inc. | Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System | NASDAQ:NXLIW | Nexalin Technologies Inc |
| 01/11/2024 | 8:30AM | GlobeNewswire Inc. | Nexalin Technology Unveils Next-Generation HALO™ Clarity | NASDAQ:NXLIW | Nexalin Technologies Inc |
| 12/18/2023 | 8:30AM | GlobeNewswire Inc. | Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression | NASDAQ:NXLIW | Nexalin Technologies Inc |
| 10/25/2023 | 8:30AM | GlobeNewswire Inc. | Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David Lasseter | NASDAQ:NXLIW | Nexalin Technologies Inc |
| 10/16/2023 | 8:30AM | GlobeNewswire Inc. | Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin’s Neurostimulation Device to Penetrate Deep Brain Structures | NASDAQ:NXLIW | Nexalin Technologies Inc |
| 08/07/2023 | 8:30AM | GlobeNewswire Inc. | Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms | NASDAQ:NXLIW | Nexalin Technologies Inc |
| 08/03/2023 | 8:30AM | GlobeNewswire Inc. | Nexalin’s CEO Mark White to be Interviewed Live on “The Big Biz Show” Today at 3PM Eastern Time | NASDAQ:NXLIW | Nexalin Technologies Inc |
| 07/26/2023 | 8:30AM | GlobeNewswire Inc. | Nexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government Agencies | NASDAQ:NXLIW | Nexalin Technologies Inc |
| 07/10/2023 | 8:30AM | GlobeNewswire Inc. | Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury | NASDAQ:NXLIW | Nexalin Technologies Inc |
| 06/01/2023 | 8:30AM | GlobeNewswire Inc. | Nexalin Technology, Inc. and Wider Come Limited Announce Joint Venture Agreement to Advance Commercialization of Nexalin’s tACS Devices in the Asia Pacific Region | NASDAQ:NXLIW | Nexalin Technologies Inc |
| 03/27/2023 | 7:00AM | GlobeNewswire Inc. | Nexalin Technology Provides 2022 Year-End Business Update | NASDAQ:NXLIW | Nexalin Technologies Inc |
| 01/24/2023 | 8:30AM | GlobeNewswire Inc. | Nexalin Technology Appoints Medical Device Veteran Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory | NASDAQ:NXLIW | Nexalin Technologies Inc |
| 01/05/2023 | 8:30AM | GlobeNewswire Inc. | Nexalin Technology CEO Provides Letter to Shareholders | NASDAQ:NXLIW | Nexalin Technologies Inc |
| 11/14/2022 | 2:00PM | GlobeNewswire Inc. | Nexalin Technology Announces Publication of a White Paper Validating its tACS Device for the Treatment of Generalized Anxiety Disorder | NASDAQ:NXLIW | Nexalin Technologies Inc |
| 09/20/2022 | 1:12PM | GlobeNewswire Inc. | Nexalin Technology, Inc. Announces Closing of $9.6 Million Initial Public Offering | NASDAQ:NXLIW | Nexalin Technologies Inc |